Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice-MedSci.cn

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice

Kim, SY; You, BH; Bae, M; Han, SY; Jung, K; Choi, YH

Choi, YH (通讯作者)，Dongguk Univ Seoul, Inst Drug Dev, Coll Pharm & Integrated Res, 32 Dongguk Ro, Goyang Si 10326, Gyeonggi Do, South Korea.;Jung, K (通讯作者)，CHA Univ, Coll Pharm, 335 Pangyo Ro, Seongnam Si 13488, Gyeonggi Do, South Korea.;Jung, K (通讯作者)，Oncobix Co Ltd, 120 Heungdeokjungang Ro, Yongin 16950, Gyeonggi Do, South Korea.

Abstract

Mirabegron (MBR) is a beta 3-adrenoceptor agonist used for treating overactive bladder syndrome. Due to its poor solubility and low bioavailability (F......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice

科室

工具

服务